The unique pharmacokinetic properties of TXA-709 may allow it to effectively treat staphylococcus aureus infections, including MRSA, while reducing the possibility of patients developing a resistance to the antibiotic. Animal model studies have shown that TXA-709, a drug being developed by TAXIS Pharmaceuticals, is more effective at combatting staph infections than the current standards of care.

In a controlled study conducted at Wayne State University, TXA-709 was more effective than daptomycin, linezolid, and vancomycin when treating multi-drug resistant strains of staph bacteria in mice. While most antibiotics of this type are delivered intravenously, an added benefit of TXA-709 is its ability to be administered orally.

Edmond J. LaVoie, PhD
Co-Founder: TAXIS Pharmaceuticals